John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.
Sci Transl Med. 2022 Sep 7;14(661):eabl8814. doi: 10.1126/scitranslmed.abl8814.
Approved therapies for tendon diseases have not yet changed the clinical practice of symptomatic pain treatment and physiotherapy. This review article summarizes advances in the development of novel drugs, biologic products, and biomaterial therapies for tendon diseases with perspectives for translation of integrated therapies. Shifting from targeting symptom relief toward disease modification and prevention of disease progression may open new avenues for therapies. Deep evidence-based clinical, cellular, and molecular characterization of the underlying pathology of tendon diseases, as well as therapeutic delivery optimization and establishment of multidiscipline interorganizational collaboration platforms, may accelerate the discovery and translation of transformative therapies for tendon diseases.
经批准的肌腱疾病治疗方法尚未改变针对症状性疼痛治疗和物理疗法的临床实践。本文综述了新型药物、生物制品和生物材料治疗肌腱疾病方面的进展,并展望了综合治疗的转化。从以缓解症状为目标转向疾病的改变和预防疾病的进展,可能为治疗开辟新的途径。深入的基于证据的肌腱疾病基础病理的临床、细胞和分子特征,以及治疗传递优化和建立多学科组织间合作平台,可能加速肌腱疾病变革性治疗的发现和转化。